KRAS and Miyoshi myopathy: Thus, our study aims to correlate the occurrence of clonal and subclonal KRAS-mutations in a MM cohort at diagnosis, treated with bortezomib-containing induction regimens, with common clinical and cytogenetic parameters, and to study the impact of the KRASp.G12A, KRASp.A146T, and KRASp.A146V mutations on survival pathways in recombinant HEK293 and MM cell line models.